Document:

Exhibit 10.1

 

Certain information marked as [****] has been excluded from this exhibit because it is both (i) not material and (ii) the type that the
Registrant treats as private or confidential.

 

Aziyo Biologics, Inc.

12510 Prosperity Drive, Suite 370

Silver Spring, MD 20904

 

June 21, 2022

 

Mr. Ronald Lloyd

[****]

[****]

 

Re:     Separation
and Release of Claims Agreement

 

Dear Ron:

 

This letter agreement (this
 “Letter Agreement”) sets forth the understanding by and between you and Aziyo Biologics, Inc. (collectively with
its affiliates, and any successor(s) thereto, the “Company”), regarding the cessation of your employment with
the Company. Capitalized terms used but not otherwise defined herein shall have the meanings assigned to such terms in that certain Employment
Agreement by and between the Company and you, dated as of September 30, 2020, (the “Employment Agreement”).

 

1.            Separation
Date. Your employment with the Company will terminate upon the expiration of the Initial Employment Period on September 30, 2022
(the “Separation Date”), and this Letter Agreement constitutes notice of termination pursuant to the terms of the Employment
Agreement. You and the Company acknowledge and agree that, notwithstanding anything to the contrary in the Employment Agreement, you hereby
resign as President and Chief Executive Officer of the Company and as a member of the Board and from all offices and positions you may
hold at the Company’s affiliates, effective as of June 21, 2022 (the “Transition Date”). During the period
beginning on the Transition Date and ending on the Separation Date (the “Transition Period”), you shall remain a full-time,
active, non-officer employee of the Company and will assist with the transition of your duties to your successor. During the Transition
Period, you will continue to receive your compensation and benefits as set forth in Section 2(b) of the Employment Agreement.
For the avoidance of doubt, you acknowledge and agree that the terms and provisions of this Letter Agreement, including, without limitation,
your transition to a non-officer employee on the Transition Date, will not constitute Good Reason under the terms of the Employment Agreement.

 

2.            Severance
Benefits. The termination of your employment on the Separation Date will be treated as a termination by the Company without Cause
pursuant to the terms of the Employment Agreement. In consideration for your execution of this Letter Agreement and good-faith cooperation
in the transition of your duties during the Transition Period, and subject to your continued compliance with the Restrictive Covenants
(as defined below) in accordance with Section 3 below and your execution and non-revocation of the Release (as defined below) in
accordance with Section 4 below and Exhibit A hereto, you shall be entitled to receive the following severance payments
and benefits (collectively, the “Severance Benefits”), in addition to the Accrued Obligations, following the Separation
Date:

 

a.            Cash
severance pursuant to Section 4(a)(i) of the Employment Agreement (or, to the extent applicable, the enhanced severance pursuant
to Section 4(a)(iii) of the Employment Agreement), calculated based on your current base salary of $548,556
and your current target bonus of $438,844.80, payable (less applicable withholdings) in accordance with the terms set forth
in the Employment Agreement (provided that, to the extent any such severance is payable in installments, any installment that is delayed
pursuant to Section 4 shall be paid in a lump-sum on the first payroll date following the date the Release becomes irrevocable in
accordance with its terms);

 

     

     

    

 

b.            An
additional cash payment in an amount equal to the difference, if any, between (i) $279,656 and (ii) the Fair Market Value (as
defined in the Company’s 2020 Incentive Award Plan (the “Equity Plan”)) as of September 8, 2022 of the 39,894
restricted stock units that will have vested in accordance with their terms on such date, payable (less applicable withholdings) in a
lump-sum on the first payroll date following the date the Release becomes irrevocable in accordance with its terms;

 

c.            Subject
to your achievement of the performance goals set forth on Exhibit B, an additional cash bonus of up to $1,000,000, payable
(less applicable withholdings) in accordance with Exhibit B; and

 

d.            The
COBRA benefits set forth in Section 4(a)(ii) of the Employment Agreement, in accordance with the terms of such Section 4(a)(ii),
during the 12-month period following the Separation Date.

 

For the avoidance of doubt, any outstanding equity
awards that you received under the Equity Plan shall be treated in accordance with the terms of the Equity Plan and the applicable award
agreements thereunder following the Separation Date. Other than the Accrued Obligations, the Severance Benefits and any rights you may
have with respect to your equity awards in accordance with their terms, you will have no further rights to any payments or benefits in
connection with the termination of your employment.

 

3.            Restrictive
Covenants. You acknowledge and agree that the Company is providing you with the Severance Benefits in material part in consideration
for your continued compliance with the following covenants (collectively, the “Restrictive Covenants”) and that no
Severance Benefits will be payable following the date that you first violate any of the Restrictive Covenants:

 

a.            You
reaffirm your prior agreement to comply with the restrictive covenants set forth in Sections 7, 8, 9 and 10 of the Employment Agreement,
which are hereby incorporated by reference herein and made a part of this Letter Agreement. For the avoidance of doubt, pursuant to Section 9(b) of
the Employment Agreement, your non-compete obligations will cease to apply on the Separation Date.

 

b.            You
acknowledge that the terms of this Letter Agreement must be kept confidential to the extent not publicly filed. Accordingly, you shall
not disclose or publish to any person or entity, except as required by law, to immediate family or as necessary to prepare tax returns
or to consult with attorneys, accountants and financial advisors, the terms and conditions of this Letter Agreement or the amount or nature
of the consideration paid or to be paid pursuant to this Letter Agreement.

  

    	 	2	 

     

    

 

c.            To
the extent permitted by law, you agree to take no action, either directly or indirectly or in any capacity or manner, or to make, express,
transmit, speak, write, verbalize or otherwise communicate in any way (or cause, further, assist, solicit, encourage, support or participate
in any of the foregoing), any remark, comment, message, information, declaration, communication or other statement of any kind, whether
verbal, in writing, electronically transferred or otherwise, (i) that might reasonably be construed to be derogatory or critical
of, or negative toward, the Company or any of its directors, officers, employees, agents or representatives (collectively, the “Company
Representatives”) (ii) that reveals, discloses, incorporates, is based upon, discusses, includes or otherwise involves
any confidential or proprietary information of the Company, (iii) that might reasonably be construed to malign, harm, disparage,
defame or damage the reputation or good name of the Company or any of the Company Representatives or (iv) that would reasonably
be expected to lead to unwanted or unfavorable publicity to the Company. Notwithstanding the foregoing, nothing herein shall prevent
you from making any truthful statement in connection with any legal proceeding or directive by any governmental authority.

 

d.            You
agree to promptly deliver to the Company as of the Separation Date (i) all correspondence, drawings, manuals, letters, notes, notebooks,
reports, programs, plans, proposals, financial documents, or any other documents that are or contain proprietary information or trade
secrets of or relating to the Company, including all physical and digital copies thereof, and (ii) all other Company property (including,
without limitation, any personal computer or wireless device and related accessories, passwords, keys, credit cards and other similar
items) which is in your possession, custody or control.

 

4.            Release.
The Severance Benefits are contingent upon and subject to your execution and non-revocation of the Waiver and Release of Claims Agreement
attached hereto as Exhibit A (the “Release”) following the Separation Date in accordance with its terms
(and you acknowledge and agree that you will not execute the Release, and the Company will not accept the Release from you, prior to the
Separation Date). No Severance Benefits will be paid or provided prior to the date the Release becomes irrevocable in accordance with
its terms and, to the extent you do not execute the Release, or you subsequently revoke the Release during the applicable revocation period,
you acknowledge and agree that you are not entitled to any Severance Benefits (provided that, for the avoidance of doubt, such failure
to execute the Release or revocation of the Release does not affect the remainder of this Letter Agreement, which shall continue in full
force and effect).

 

5.            Non-Admission
of Liability. The Company’s agreements herein shall not be construed as evidence or an admission of liability or of otherwise
unlawful actions or practices on the part of the Company and the Company expressly denies all liability and alleged wrongful actions.

 

6.            Section 409A.
It is intended that the Severance Benefits, to the greatest extent possible, comply with or satisfy an exemption from the application
of Section 409A and shall be interpreted to be consistent therewith. In this regard, Sections 4(c) and 13(f) of the Employment
Agreement are hereby incorporated by reference and made a part of this Letter Agreement.

 

    	 	3	 

     

    

 

7.            Entire
Agreement. This Letter Agreement sets forth the entire agreement between you and the Company with respect to the subject matter set
forth herein and supersedes and replaces any and all prior oral or written agreements or understandings between you and the Company with
respect to the subject matter hereof (including, without limitation, the Employment Agreement); provided, that, for the avoidance
of doubt, the provisions of the Employment Agreement which by their terms survive termination of employment will remain in full force
and effect in accordance with their terms (as may be amended by this Letter Agreement). This Letter Agreement may be amended only by a
subsequent writing signed by both parties. You represent that you have signed this Letter Agreement knowingly and voluntarily.

 

[signature page follows]

 

    	 	4	 

     

    

 

Please
indicate your acceptance of the terms and provisions of this Letter Agreement by signing both copies of this Letter Agreement and returning
one copy to me. The other copy is for your files. By signing below, you acknowledge and agree that you have carefully read this Letter
Agreement, Exhibit A and Exhibit B hereto in their entirety; fully understand and agree to their terms and provisions;
have received good, valuable and sufficient consideration for your agreement to execute and comply with this Letter Agreement; will comply
with the Restrictive Covenants; and intend and agree that this Letter Agreement is final and legally binding on you and the Company. All
payments described in this Letter Agreement will be subject to the withholding of any amounts required by federal, state or local law.
This Letter Agreement will be governed and construed under the internal laws of the State of California and may be executed in several
counterparts.

 

	 	Very truly yours,
	 	 
	 	/s/ Kevin Rakin
	 	Kevin Rakin
	 	On behalf of Aziyo Biologics, Inc.

 

    	 	5	 

     

    

 

Agreed, Acknowledged and Accepted as of the first date set forth above:

 

	/s/
    Ronald Lloyd	 
	Ronald Lloyd	 

 

    	 	6	 

     

    

 

EXHIBIT A

 

RELEASE OF CLAIMS

 

For valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever discharge the “Releasees”
hereunder, consisting of Aziyo Biologics, Inc., (the “Company”) and its partners, subsidiaries, associates, affiliates,
successors, heirs, assigns, agents, directors, officers, employees, representatives, lawyers, insurers, and all persons acting by, through,
under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law
or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs, attorneys’
fees or expenses, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which
the undersigned now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever
from the beginning of time to the date hereof.  The Claims released herein include, without limiting the generality of the foregoing,
any Claims in any way arising out of, based upon, or related to the employment or termination of employment of the undersigned by the
Releasees, or any of them; any alleged breach of any express or implied contract of employment; any alleged torts or other alleged legal
restrictions on Releasees’ right to terminate the employment of the undersigned; and any alleged violation of any federal, state
or local statute or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment
Act, the Americans With Disabilities Act, the California Fair Employment and Housing Act; the California Family Rights Act; the California
Labor Code; and California Business & Professions Code Section 17200. Notwithstanding the foregoing, this general release
(the “Release”) shall not operate to release any rights or claims of the undersigned (i) to payments or benefits
under that certain Letter Agreement dated as of June 21, 2022 by and between the undersigned , to which this Release is attached
as an exhibit, (ii) to payments or benefits under any equity award agreement between the undersigned and the Company, (iii) to
reimbursement of expenses pursuant to Section 2(b)(iv) of the Employment Agreement dated as of September 30, 2020 by and
between the undersigned and the Company, (iv) to accrued or vested benefits the undersigned may have, if any, as of the date hereof
under any applicable plan, policy, practice, program, contract or agreement with the Company, (v) to any Claims, including claims
for indemnification and/or advancement of expenses arising under any indemnification agreement between the undersigned and the Company
or under the bylaws, certificate of incorporation or other similar governing document of the Company, (vi) to any Claims which cannot
be waived by an employee under applicable law or (vii) with respect to the undersigned’s right to communicate directly with,
cooperate with, or provide information to, any federal, state or local government regulator.

 

IN ACCORDANCE WITH THE OLDER
WORKERS BENEFIT PROTECTION ACT OF 1990, THE UNDERSIGNED IS HEREBY ADVISED AS FOLLOWS:

 

(A)            THE
EXECUTIVE HAS THE RIGHT TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE;

 

(B)            THE
EXECUTIVE HAS TWENTY-ONE (21) DAYS TO CONSIDER THIS RELEASE BEFORE SIGNING IT; AND

 

(C)            THE
EXECUTIVE HAS SEVEN (7) DAYS AFTER SIGNING THIS RELEASE TO REVOKE THIS RELEASE, AND THIS RELEASE WILL BECOME EFFECTIVE UPON THE EXPIRATION
OF THAT REVOCATION PERIOD.

 

The undersigned represents and
warrants that there has been no assignment or other transfer of any interest in any Claim which the Executive may have against Releasees,
or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability, Claims, demands,
damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any such assignment or transfer
or any rights or Claims under any such assignment or transfer.  It is the intention of the parties that this indemnity does not require
payment as a condition precedent to recovery by the Releasees against the undersigned under this indemnity.

 

    	 	7	 

     

    

 

Notwithstanding anything herein,
the undersigned acknowledges and agrees that, pursuant to 18 USC Section 1833(b), the undersigned will not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of a trade secret that is made: (i) in confidence to
a federal, state, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting
or investigating a suspected violation of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if
such filing is made under seal.

 

The undersigned agrees that
if the Executive hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder or in any
manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to pay to Releasees,
and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred by Releasees in defending
or otherwise responding to said suit or Claim.

 

The undersigned further understands
and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed as an admission
of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they have no liability whatsoever
to the undersigned.

 

IN WITNESS WHEREOF, the undersigned
has executed this Release this ____ day of ___________, ____.

 

	 	 
	 	Ronald Lloyd

 

    	 	8	 

     

    

 

EXHIBIT B

 

[****]Exhibit 10.2

 

Execution Version

 

EMPLOYMENT
AGREEMENT

 

THIS EMPLOYMENT AGREEMENT (this
 “Agreement”), entered into as of June 21, 2022 (the “Effective Date”), is made
by and between Aziyo Biologics, Inc. (the “Company”) and C. Randal Mills (the “Executive”)
(collectively referred to herein as the “Parties”).

 

WHEREAS, the Company desires
to employ the Executive as its Interim President and Chief Executive Officer, with the prospect of Executive assuming the President and
Chief Executive Officer (“CEO”) roles on a non-interim basis if requested to do so by the Board; and

 

WHEREAS, the Executive desires
to provide services to the Company on the terms herein provided;

 

NOW, THEREFORE, IT IS HEREBY
AGREED AS FOLLOWS:

 

1.            Employment
Period. The Executive and Company agree to an interim period beginning on the Effective Date and ending on the date that is ninety
(90) days following the Effective Date (“Interim Period”), during which the Executive will have the title Interim
President and CEO. During the Interim Period, Executive, along with the Company’s Board of Directors (“Board”) as represented
by the Board Chair, will evaluate the strategic and leadership needs of the Company prior to selecting a non-interim President and CEO.
Executive shall be compensated and shall receive benefits in accordance with this Agreement during the Interim Period. Notwithstanding
anything to the contrary in this Section 1, if at any time prior to the expiration of the Interim Period, both the Executive and
the Board agree that the Executive is suitable to assume the role of president and CEO on a non-interim basis, then the Parties will confirm
that fact in writing, and the Interim Period will end effective on the date of such writing and the remaining terms of this Agreement
will take effect immediately. If at the end of the Interim Period, either the Company or the Executive or both Parties find that the Executive,
for any reason, should not assume the role of non-interim President and CEO, this Agreement will terminate on the last day of the Interim
Period without the Company having any severance obligations to the Executive. Subject to the Interim Period as described immediately above
and the provisions for earlier termination provided for in Sections 3 and 4, the Executive’s employment will commence on the Effective
Date and will continue until it is terminated by either Party in accordance with this Agreement (“Employment Period”).

 

 2.             Terms of Employment.

 

(a)            Position
and Duties.

 

(i)            Role
and Responsibilities. During the Employment Period, the Executive shall serve as President and Chief Executive Officer of the Company,
shall continue to serve as a member of the Board of Directors of the Company, and shall perform such employment duties as are usual and
customary for such positions. The Executive shall report directly to the Board of Directors of the Company (the “Board”).
At the Company’s request, the Executive shall serve the Company and/or its subsidiaries and affiliates in other capacities in addition
to the foregoing, consistent with the Executive’s position as President and Chief Executive Officer of the Company. In the event
that the Executive, during the Employment Period, serves in any one or more of such additional capacities, the Executive’s compensation
shall not be increased beyond that specified in Section 2(b) hereof. In addition, in the event the Executive’s service
in one or more of such additional capacities is terminated, the Executive’s compensation, as specified in Section 2(b) hereof,
shall not be diminished or reduced in any manner as a result of such termination provided that the Executive otherwise remains
employed under the terms of this Agreement.

 

     

     

    

 

(ii)            Exclusivity.
During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive may be entitled, the Executive
agrees to devote his full business time and attention to the business and affairs of the Company. Notwithstanding the foregoing, during
the Employment Period, it shall not be a violation of this Agreement for the Executive to: (A) serve on boards, committees or similar
bodies of charitable or nonprofit organizations, and the board of one non-competitive for-profit corporation or organization, (B) fulfill
limited teaching, speaking and writing engagements, and (C) manage his or her personal investments, in each case, so long as such
activities do not individually or in the aggregate materially interfere or conflict with the performance of the Executive’s duties
and responsibilities under this Agreement; provided, that with respect to the activities in subclauses (A) and/or (B), the
Executive receives prior written approval from the Board, which shall not be unreasonably withheld. Exhibit A of this Agreement
sets forth the board of directors or advisory boards on which the Executive currently serves, which are approved by the Board.

 

(iii)            Principal
Location. During the Employment Period, the Executive shall perform the services required by this Agreement at the Company’s
San Diego office(the “Principal Location”) and may from time to time travel to other locations as necessary
to fulfill the Executive’s duties and responsibilities hereunder.

 

(b)            Compensation,
Benefits, Etc.

 

(i)            Base
Salary. During the Employment Period, the Executive shall initially receive a base salary (the “Base Salary”)
of $600,000 per annum. The Company acknowledges that the Base Salary is below market for an individual of Executive’s experience
and skills in a President/CEO position and agrees to adjust Executive’s compensation, in accordance with recommendations of its
compensation consultant, to reflect market-level compensation as soon as reasonably practicable, without regard to whether the timing
of such an adjustment coincides with an annual performance/compensation review. The Base Salary shall be reviewed at least annually by
the Compensation Committee (the “Compensation Committee”) of the Board. The Base Salary shall be paid in accordance
with the Company’s normal payroll practices for executive salaries generally, but no less often than monthly. The Base Salary may
be increased in the Compensation Committee’s discretion, but not reduced, and the term “Base Salary” as utilized in
this Agreement shall refer to the Base Salary as so increased.

 

(ii)            Annual
Cash Bonus. In addition to the Base Salary, the Executive shall be eligible to earn, for each fiscal year of the Company ending during
the Employment Period, a discretionary cash performance bonus (an “Annual Bonus”) under the Company’s
bonus plan or program applicable to senior executives. The Executive’s target Annual Bonus shall be set at 60% of the Base Salary
actually paid for such year (the “Target Bonus”). The actual amount of any Annual Bonus for a fiscal year shall
be determined by reference to the attainment of Company performance metrics and/or individual performance objectives, in each case, as
established by the Compensation Committee for such fiscal year and communicated to the Executive no later than the end of the first month
of such fiscal year, and may be greater or less than the Target Bonus (or zero), provided that, notwithstanding the foregoing,
the Executive shall be entitled to receive a guaranteed Target Bonus for the first 12 months of the Employment Period, provided
that for fiscal year 2022, the Annual Bonus will be pro-rated based upon the portion of the fiscal year beginning on the Effective Date
and ending on the last day of the fiscal year. Subject to Section 4(a)(i) hereof, payment of any Annual Bonus(es), to the extent
any Annual Bonus(es) become payable, will be contingent upon the Executive’s continued employment through the last day of the applicable
fiscal year. The Company will pay any such bonus that has been duly earned and awarded by the Board as soon as administratively possible
following its approval by the Board and, in any event, no later than the later of (i) the fifteenth day of the third month after
the end of the Company’s fiscal year in which such bonus is earned or (ii) March 15 immediately following the calendar
year in which such bonus is earned. The Target Bonus may be increased in the Compensation Committee’s discretion based on the success
of the Company’s business.

 

    2

     

    

 

(iii)            Equity
Awards. Subject to approval by the Board, the Company shall grant equity awards to the Executive under the Company’s 2020 Incentive
Award Plan (as amended from time to time, the “Equity Plan”) and pursuant to the terms and conditions of one
or more award agreements thereunder, as follows:

 

(A)            On
the Effective Date, the Executive shall be granted Options (as defined in the Equity Plan) to purchase 273,767 shares of Common Stock
(as defined in the Equity Plan) at a price per share equal to the Fair Market Value (as defined in the Equity Plan) of a share of Common
Stock on the date of grant (the “Time Vesting Options”) and Options to purchase 182,511 shares of Common Stock
at a price per share equal to the Fair Market Value of a share of Common Stock on the date of grant (the “Performance Vesting
Options”).

 

(B)            As
soon as reasonably practicable following the Effective Date, and in any event no later than March 15, 2023, the Executive shall be
granted Restricted Stock Units (as defined in the Equity Plan) covering 134,840 shares of Common Stock (the “Time Vesting
RSUs”) and Restricted Stock Units covering 89,894 shares of Common Stock (the “Performance Vesting RSUs”).

 

(C)            Subject
to the Executive’s continued employment through each vesting date, (x) the Time Vesting Options and Time Vesting RSUs shall
vest with respect to one-third of the shares covered thereby upon the day following the expiration of the Interim Period (provided
that, if the Executive is willing to assume the role of non-interim President and CEO but the Company determines that he should not assume
that role, such one-third Time Vesting Options and Time Vesting RSUs shall become vested notwithstanding the Executive’s termination
of employment on or prior to the vesting date); (y) the remaining two-thirds of the shares covered by the Time Vesting Options shall
vest (1) with respect to 25% of the shares covered thereby on the first anniversary of the Effective Date, and (2) with respect
to 75% of the shares covered thereby in twelve equal quarterly installments, beginning on the first quarterly anniversary following the
first anniversary of the Effective Date; and (z) the remaining two-thirds of the shares covered by the Time Vesting RSUs shall vest
in four equal annual installments on each of the first four anniversaries of the Effective Date, such that 100% of the Time Vesting Options
and Time Vesting RSUs shall be vested as of the fourth anniversary of the Effective Date.    Subject to the Executive’s
continued employment through each vesting date, the Performance Vesting Options and the Performance Vesting RSUs shall each vest in four
equal installments upon the Company’s achievement of, respectively, a share price of $12.50, $17.00, $25.00 and $37.00, in each
case, determined based on twenty consecutive days trading at or above the applicable threshold.  In the event that the Company does
not have adequate outstanding shares reserved under the Equity Plan to grant the Time Vesting RSUs and Performance Vesting RSUs prior
to any applicable vesting date, any Restricted Stock Units that would have otherwise vested on such vesting date shall be vested on the
grant date (which grant date, for the avoidance of doubt, shall be no later than March 15, 2023).

 

    3

     

    

 

(iv)            Benefits.
During the Employment Period, the Executive (and the Executive’s spouse and/or eligible dependents to the extent provided in the
applicable plans and programs) shall be eligible to participate in and be covered under the health and welfare benefit plans and programs
maintained by the Company for the benefit of its employees from time to time, pursuant to the terms of such plans and programs, including
any medical and dental insurance plans and programs. In addition, during the Employment Period, Executive shall be eligible to participate
in any retirement, savings and other employee benefit plans and programs maintained from time to time by the Company for the benefit of
its senior executive officers. Nothing contained in this Section 2(b)(iv) shall create or be deemed to create any obligation
on the part of the Company to adopt or maintain any health, welfare, retirement or other benefit plan or program at any time or to create
any limitation on the Company’s ability to modify or terminate any such plan or program.

 

(v)            Expenses.
During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable business expenses incurred
by the Executive in accordance with the policies, practices and procedures of the Company provided to employees of the Company.

 

(vi)            Fringe
Benefits. During the Employment Period, the Executive shall be eligible to receive such fringe benefits and perquisites as are provided
by the Company to its employees from time to time, in accordance with the policies, practices and procedures of the Company, and shall
receive such additional fringe benefits and perquisites as the Company may, in its discretion, from time-to-time provide.

 

(vii)            Vacation.
During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the plans, policies, programs and practices
of the Company applicable to its senior executives in effect from time to time, but in no event shall the Executive be entitled to less
than four (4) weeks of vacation per calendar year (pro-rated for any partial year of service).

 

3.            Termination
of Employment. The provisions of this Section shall apply only after the conclusion of the Interim Period.

 

(a)            Death
or Disability. The Executive’s employment shall terminate automatically upon the Executive’s death during the Employment
Period. Either the Company or the Executive may terminate the Executive’s employment in the event of the Executive’s Disability
during the Employment Period. For purposes of this Agreement, “Disability” shall mean any disability or incapacity
that (i) renders Executive unable to substantially perform his duties hereunder for ninety (90) days during any 12-month period or
(ii) would reasonably be expected to render Executive unable to substantially perform his duties for ninety (90) days during any
12-month period, in each case as determined by the Board in its good faith judgment; provided that the Company shall comply with
any applicable accommodation requirements of the Americans with Disabilities Act prior to any such termination for Disability.

 

    4

     

    

 

(b)            Termination
by the Company. The Company may terminate the Executive’s employment during the Employment Period for Cause or without Cause.
For purposes of this Agreement, “Cause” shall mean the occurrence of any one or more of the following events
unless, to the extent capable of correction, the Executive fully corrects the circumstances constituting Cause within fifteen (15) days
after receipt of the Notice of Termination (as defined below):

 

(i)            the
Executive performing his duties in a grossly negligent or reckless manner or with willful malfeasance;

 

(ii)            the
Executive exhibiting habitual drunkenness or engaging in substance abuse;

 

(iii)            the
Executive committing any material violation of any state or federal law relating to the workplace environment (including, without limitation,
laws relating to sexual harassment or age, sex or other prohibited discrimination); or any material violation of any material Company
policy;

 

(iv)            the
Executive willfully failing or refusing to perform in the usual manner at the usual time those duties which he regularly and routinely
performs in connection with the business of the Company or such other duties reasonably related to the capacity in which he is employed
hereunder which may be assigned to him by the Board;

 

(v)            the
Executive performing any material action when specifically and reasonably instructed not to do so by the Chairman or the Board;

 

(vi)            the
Executive breaching Sections 7, 8 and 9 hereof;

 

(vii)            the
Executive committing any fraud or using or appropriating for his or her personal use or benefit any funds, properties or opportunities
of the Company not authorized by the Board to be so used or appropriated; or

 

(viii)            the
Executive being convicted of any felony or any other crime related to his employment. or involving moral turpitude.

 

The Company shall not be entitled to terminate
Executive for Cause pursuant to clause (iii), (iv), (v) or (vi) unless the Company provides written notice stating in reasonable
detail the basis for termination and a thirty (30) day opportunity to cure to Executive (unless (1) the Company reasonably determines
that providing such opportunity to cure to Executive is reasonably likely to have a material adverse effect on its business, financial
condition, results of operations, prospects or assets, (2) the facts and circumstances underlying such termination are not able to
be cured or (3) the Company has previously provided Executive a thirty (30) day opportunity to cure the applicable issue; in the
case of (1), (2) or (3), the Company may terminate Executive without providing an opportunity to cure).

 

(c)            Termination
by the Executive. The Executive’s employment may be terminated by the Executive for any reason, including with Good Reason or
by the Executive without Good Reason. For purposes of this Agreement, “Good Reason” shall mean the occurrence
of any one or more of the following events without the Executive’s prior written consent, unless the Company fully corrects the
circumstances constituting Good Reason (provided such circumstances are capable of correction) as provided below:

 

(i)            A
material reduction in the Executive’s job responsibilities and duties for the Company;

 

(ii)            A
material reduction in the Executive’s Base Salary; or

 

(iii)            a
requirement imposed by the Company on the Executive that Executive’s principal place of employment be anywhere other than within
a 50 mile radius of the Executive’s Principal Location, except for required travel on Company business to an extent substantially
consistent with Executive's business travel obligations, that, in any such case, is not cured by the Company within fifteen (15) days
after the Company’s receipt of written notice from the Executive of such event.

 

    5

     

    

 

(iv)  Notwithstanding
the foregoing, the Executive will not be deemed to have resigned for Good Reason unless (1) the Executive provides the Company with
written notice setting forth in reasonable detail the facts and circumstances claimed by the Executive to constitute Good Reason within
sixty (60) days after the date of the initial occurrence of any event that the Executive knows or should reasonably have known to constitute
Good Reason, (2) the Company fails to cure such acts or omissions within thirty (30) days following its receipt of such notice, and
(3) the effective date of the Executive’s termination for Good Reason occurs no later than sixty (60) days after the expiration
of the Company’s cure period.

 

(d)            Notice
of Termination. Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by a Notice of
Termination to the other parties hereto given in accordance with Section 13(d) hereof. For purposes of this Agreement, a “Notice
of Termination” means a written notice which (i) indicates the specific termination provision in this Agreement relied
upon, (ii) sets forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of the Executive’s
employment under the provision so indicated and (iii) if the Date of Termination (as defined below) is other than the date of receipt
of such notice, specifies the termination date (which date shall be not more than thirty (30) days after the giving of such notice). The
failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing
of Good Reason or Cause shall not waive any right of the Executive or the Company, respectively, hereunder or preclude the Executive or
the Company, respectively, from asserting such fact or circumstance in enforcing the Executive’s or the Company’s rights hereunder.

 

(e)            Termination
of Offices and Directorships; Return of Property. Upon termination of the Executive’s employment for any reason, unless otherwise
specified in a written agreement between the Executive and the Company, the Executive shall be deemed to have resigned from all offices,
directorships, and other employment positions if any, then held with the Company and shall take all actions reasonably requested by the
Company to effectuate the foregoing, provided that Executive shall not resign his position as a Board member in the event of his termination
of employment upon the expiration of the Interim Period and, subject to mutual agreement between the Parties, may otherwise retain his
position as a Board member following a termination under this Section other than for Cause. In addition, upon the termination of
the Executive’s employment for any reason, the Executive agrees to return to the Company all documents of the Company and its affiliates
(and all copies thereof) and all other Company or Company affiliate property that the Executive has in his or her possession, custody
or control. Such property includes, without limitation: (i) any materials of any kind that the Executive knows contain or embody
any proprietary or confidential information of the Company or an affiliate of the Company (and all reproductions thereof), (ii) computers
(including, but not limited to, laptop computers, desktop computers and similar devices) and other portable electronic devices (including,
but not limited to, tablet computers), cellular phones/smartphones, credit cards, phone cards, entry cards, identification badges and
keys, and (iii) any correspondence, drawings, manuals, letters, notes, notebooks, reports, programs, plans, proposals, financial
documents, or any other documents concerning the customers, business plans, marketing strategies, products and/or processes of the Company
or any of its affiliates and any information received from the Company or any of its affiliates regarding third parties.

 

4.            Obligations
of the Company upon Termination. Upon a termination of the Executive’s employment for any reason, the Executive shall be paid,
in a single lump-sum payment on the date of the Executive’s termination of employment, the aggregate amount of the Executive’s
earned but unpaid Base Salary and accrued but unpaid vacation pay through the date of such termination (the “Accrued Obligations”).

 

    6

     

    

 

(a)            Without
Cause or For Good Reason. If the Executive’s employment with the Company as the non-interim President and CEO is terminated
during the Employment Period (x) by the Company without Cause (other than by reason of the Executive’s death or Disability
or due to the expiration of the Employment Period) or (y) by the Executive for Good Reason (in either case, a “Qualifying
Termination”), then following the Executive’s Separation from Service (as defined below) (such date, the “Date
of Termination”), in each case, subject to and conditioned upon compliance with Section 4(d) hereof, in addition
to the Accrued Obligations:

 

(i)            Cash
Severance. The Company shall continue to pay to the Executive the sum of (A) the Executive’s Base Salary in effect on the
Date of Termination and (B) the Target Bonus for the year in which the Date of Termination occurs during the period beginning on
the Date of Termination and ending on the 12-month anniversary of the Date of Termination (the “Severance Period”)
in installments in accordance with the Company’s normal payroll practices for executive salaries generally as of the Date of Termination,
but no less often than monthly;

 

(ii)  COBRA.
The Company will pay the Executive a lump sum in cash, within 60 days following the Date of Termination, an amount equal to twelve (12)
times the Company’s monthly charge in effect on the Date of Termination for continuation of coverage under the Company’s group
health plan for the type of coverage in effect for the Executive (e.g., family coverage) on the Date of Termination.

 

(iii) Change
in Control. Notwithstanding the foregoing, if the Qualifying Termination occurs within the 12-month period following a Change in Control
or within the 3-month period prior to a Change in Control, as defined in the Equity Plan (and such Change in Control constitutes a “change
in control event” as defined in Treasury Regulations Section 1.409A-3(i)(5)), then in lieu of the foregoing payments set forth
in Section 4(a)(i), the Company shall pay to the Executive in a lump sum in cash, on the first payroll date following the date the
Release (as defined below) becomes irrevocable in accordance with its terms following the Date of Termination or, if later, the effective
date of the Change in Control, an amount equal to the sum of (x) 18-months of Executive’s Base Salary in effect on the Date
of Termination, (y) 1.5 times the Executive’s Target Bonus for the year in which the Date of Termination occurs, and (z) eighteen
(18) times the Company’s monthly charge in effect on the Date of Termination for continuation of coverage under the Company’s
group health plan for the type of coverage in effect for the Executive (e.g., family coverage) on the Date of Termination. In addition,
unless otherwise explicitly set forth in any award agreement, any unvested equity awards outstanding immediately prior to the Date of
Termination shall automatically become fully vested and exercisable (as applicable).

 

Notwithstanding the foregoing, it shall be a condition
to the Executive’s right to receive the amounts provided for in Sections 4(a)(i), 4(a)(ii) and 4(a)(iii) hereof that the
Executive execute and deliver to the Company an effective release of claims in substantially the form attached hereto as Exhibit B
(the “Release”), which the Company shall provide to the Executive within seven (7) days following the Date
of Termination, within twenty-one (21) days (or, to the extent required by law, forty-five (45) days) following the Date of Termination
and that the Executive not revoke such Release during any applicable revocation period.

 

(b)            For
Cause or Without Good Reason Termination. If the Company terminates the Executive’s employment for Cause or the Executive terminates
the Executive’s employment without Good Reason, the Company shall pay to the Executive the Accrued Obligations in cash within thirty
(30) days after the Date of Termination (or by such earlier date as may be required by applicable law), and the Executive shall have no
further rights hereunder.

 

    7

     

    

 

(c)            Six-Month
Delay. Notwithstanding anything to the contrary in this Agreement, no compensation or benefits, including without limitation any severance
payments or benefits payable under Section 4 hereof, shall be paid to the Executive during the six (6)-month period following the
Executive’s “separation from service” from the Company (within the meaning of Section 409A, a “Separation
from Service”) if the Company determines that paying such amounts at the time or times indicated in this Agreement would
be a prohibited distribution under Section 409A(a)(2)(B)(i) of the Code. If the payment of any such amounts is delayed as a
result of the previous sentence, then on the first day of the seventh month following the date of Separation from Service (or such earlier
date upon which such amount can be paid under Section 409A without resulting in a prohibited distribution, including as a result
of the Executive’s death), the Company shall pay the Executive a lump-sum amount equal to the cumulative amount that would have
otherwise been payable to the Executive during such period.

 

(d)            Exclusive
Benefits. Except as expressly provided in this Section 4 and subject to Section 5 hereof, the Executive shall not be entitled
to any additional payments or benefits upon or in connection with the Executive’s termination of employment.

 

5.            Non-Exclusivity
of Rights. Amounts which are vested benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice
or program of or any contract or agreement with the Company at or subsequent to the Date of Termination shall be payable in accordance
with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement.

 

6.            Excess
Parachute Payments, Limitation on Payments.

 

(a)            Best
Pay Cap. Notwithstanding any other provision of this Agreement, in the event that any payment or benefit received or to be received
by the Executive (including any payment or benefit received in connection with a termination of the Executive’s employment, whether
pursuant to the terms of this Agreement or any other plan, arrangement or agreement) (all such payments and benefits, including the payments
and benefits under Section 4 hereof, being hereinafter referred to as the “Total Payments”) would be subject
(in whole or part), to the excise tax imposed under Section 4999 of the Code (the “Excise Tax”), then,
after taking into account any reduction in the Total Payments provided by reason of Section 280G of the Code in such other plan,
arrangement or agreement, the cash severance payments under this Agreement shall first be reduced, and the noncash severance payments
hereunder shall thereafter be reduced, to the extent necessary so that no portion of the Total Payments is subject to the Excise Tax but
only if (i) the net amount of such Total Payments, as so reduced (and after subtracting the net amount of federal, state and local
income taxes on such reduced Total Payments and after taking into account the phase out of itemized deductions and personal exemptions
attributable to such reduced Total Payments) is greater than or equal to (ii) the net amount of such Total Payments without such
reduction (but after subtracting the net amount of federal, state and local income taxes on such Total Payments and the amount of Excise
Tax to which the Executive would be subject in respect of such unreduced Total Payments and after taking into account the phase out of
itemized deductions and personal exemptions attributable to such unreduced Total Payments).

 

(b)            Certain
Exclusions. For purposes of determining whether and the extent to which the Total Payments will be subject to the Excise Tax, (i) no
portion of the Total Payments the receipt or enjoyment of which the Executive shall have waived at such time and in such manner as not
to constitute a “payment” within the meaning of Section 280G(b) of the Code shall be taken into account; (ii) no
portion of the Total Payments shall be taken into account which, in the written opinion of an independent, nationally recognized accounting
or consulting firm (the “Independent Advisors”) selected by the Company, does not constitute a “parachute
payment” within the meaning of Section 280G(b)(2) of the Code (including by reason of Section 280G(b)(4)(A) of
the Code) and, in calculating the Excise Tax, no portion of such Total Payments shall be taken into account which, in the opinion of the
Independent Advisors, constitutes reasonable compensation for services actually rendered, within the meaning of Section 280G(b)(4)(B) of
the Code, in excess of the “base amount” (as defined in Section 280G(b)(3) of the Code) allocable to such reasonable
compensation; and (iii) the value of any non-cash benefit or any deferred payment or benefit included in the Total Payments shall
be determined by the Independent Advisors in accordance with the principles of Sections 280G(d)(3) and (4) of the Code.

 

    8

     

    

 

7.            Nondisclosure
and Nonuse of Confidential Information.

 

(a)            The
Executive’s employment creates a relationship of confidence and trust between the Company and the Executive with respect to any
information that is applicable to the business of the Company or the affiliates, any information that is otherwise used, developed or
obtained by the Company or any affiliate in connection with its business and any information that is applicable to the business of any
client, customer or other commercial partner of the Company or the affiliates, which may be made known to the Executive or learned by
the Executive in such context during the period of his employment with the Company. All such information, whether oral or written, has
commercial value in the business in which the Company is engaged and is referred to herein as “Confidential Information”.

 

(b)            The
Company owns all right, title and interest in and to all Confidential Information. The Executive hereby assigns to the Company all right,
title and interest that he may have acquired or hereafter may acquire in all Confidential Information. The Executive shall, at all times,
both during the Employment Period and after the termination of the Employment Period, keep in confidence and trust all Confidential Information
and the Executive shall not use or disclose any Confidential Information except as may be necessary in the ordinary course of performing
his duties as an employee of the Company. Upon termination of the Employment Period, or at any time upon the request of the Company before
such termination, the Executive shall promptly (but no later than five (5) days after the earlier of such termination or such request)
destroy or deliver to the Company, at the Company’s option, all Confidential Information in the Executive’s control or possession
and a written certification of the Executive’s compliance with such obligations.

 

(c)            the
Executive hereby represents and warrants to the Company that neither his performance of the terms of this Agreement nor his employment
with the Company will breach or conflict with any agreement, understanding, policy or other arrangement that he is a party to or otherwise
subject to or bound by (including, without limitation, any such agreement, understanding, policy or arrangement (i) relating to nondisclosure
or nonuse of proprietary information, knowledge or data or (ii) that otherwise assigns, licenses or otherwise transfers any interest
in or to any Company Innovation (as defined below) to person or entity other than the Company). The Executive shall not disclose to the
Company or otherwise use any confidential or proprietary information or material belonging to any other person or entity.

 

(d)            Notice
of Immunity Under the Economic Espionage Act of 1996, as amended by the Defend Trade Secrets Act of 2016 (“DTSA”).
Notwithstanding any other provision of this Agreement:

 

(e)            the
Executive will not be held criminally or civilly liable under any federal or state trade secret law for any disclosure of a trade secret
that: (A) is made: (1) in confidence to a federal, state, or local government official, either directly or indirectly, or to
an attorney; and (2) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a
complaint or other document that is filed under seal in a lawsuit or other proceeding.

 

(f)            If
the Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, the Executive may disclose the
Company’s trade secrets to the Executive’s attorney and use the trade secret information in the court proceeding if the Executive:
(A) files any document containing the trade secret under seal; and (B) does not disclose the trade secret, except pursuant to
court order.

 

    9

     

    

 

(g)            the
Executive shall (i) comply with all Company security policies and procedures as in force from time to time including, without limitation,
those regarding computer equipment, telephone systems, voicemail systems, facilities access, monitoring, key cards, access codes, Company
intranet, internet, social media and instant messaging systems, e-mail systems, document storage systems, software licenses, data security,
encryption, firewalls and passwords (the “Facilities and Information Technology Resources”); (ii) not access
or use any Facilities and Information Technology Resources except as authorized by the Company; and (iii) not access or use any Facilities
and Information Technology Resources in any manner after the termination of the Executive’s employment by the Company,
whether termination is voluntary or involuntary.

 

8.            Inventions
and Proprietary Rights.

 

(a)            the
Executive represents and warrants to the Company that he does not have any right, title or interest in or to any Innovation (as defined
below) applicable to the business of the Company or relating in any way to the Company’s business or demonstrably anticipated research
and development or business that were conceived, reduced to practice, created, derived, developed or made by the Executive prior to the
date hereof.

 

(b)            the
Executive hereby agrees promptly to disclose and describe to the Company, and the Executive hereby assigns to the Company all right, title
and interest in and to, each of the Innovations and all associated intellectual property rights that the Executive may solely or jointly
conceive, reduce to practice, create, derive, develop or make during the period of his employment with the Company that (i) relate
to the Company’s or any affiliate’s business or actual or demonstrably anticipated research or development, (ii) were
developed on any amount of the Company’s or any affiliate’s time or with the use of any of the Company’s or any affiliate’s
materials, equipment, supplies, facilities or information or (iii) resulted from any work that the Executive performed for the Company
or any affiliate (collectively, the “Company Innovations”). the Executive further acknowledges and agrees that
all Company Innovations, including, without limitation, any computer programs, programming documentation, and other works of authorship,
are “works made for hire” for purposes of the Company’s rights under copyright laws and the Executive hereby assigns
to the Company any and all right, title and interest that the Executive may have acquired or may hereafter acquire in such Company Innovations.
Any assignment of copyright hereunder includes all rights of paternity, integrity, disclosure and withdrawal and any other rights that
may be known as or referred to as “moral rights” (collectively “Moral Rights”). To the extent that
such Moral Rights cannot be assigned under applicable law and to the extent the following is allowed by the laws in the various countries
where Moral Rights exist, the Executive hereby waives such Moral Rights and consents to any action of the Company and the affiliates that
would violate such Moral Rights in the absence of such consent. The Executive shall confirm any such waivers and consents from time to
time as requested by the Company. To the extent that any right, title or interest in or to any Company Innovation cannot be assigned by
the Executive to the Company, the Executive hereby grants to the Company an exclusive, royalty-free, transferable, irrevocable, worldwide
license (with rights to sublicense through multiple tiers of sublicensees) to practice such non-assignable right, title or interest. To
the extent that any right, title or interest in or to any Company Innovation can be neither assigned nor licensed by the Executive to
the Company, the Executive hereby irrevocably waives and agrees never to assert such non-assignable and non-licensable right, title or
interest against the Company, any affiliate or any of their successors in interest to such non-assignable and non-licensable rights.

 

(c)            the
Executive recognizes that Innovations and Confidential Information relating to his activities while working for the Company and conceived,
reduced to practice, created, derived, developed or made by the Executive, alone or with others, within six (6) months after termination
of his employment with the Company may have been conceived, reduced to practice, created, derived, developed or made, as applicable, in
significant part while employed by the Company. Accordingly, the Executive agrees that such Innovations and Confidential Information shall
be presumed to have been conceived, reduced to practice, created, derived, developed or made, as applicable, during his employment with
the Company and shall be assigned to the Company unless and until the Executive has established the contrary by written evidence satisfying
the clear and convincing standard of proof.

 

    10

     

    

 

(d)            the
Executive shall perform, during and after his employment with the Company, all acts deemed necessary or desirable by the Company to permit
and assist the Company, at the Company’s expense, in obtaining and enforcing the full benefits, enjoyment, rights and title throughout
the world in the Confidential Information and Innovations assigned or licensed to, or whose rights are irrevocably waived and shall not
be asserted against, the Company and the affiliates under this Agreement. Such acts may include, but are not limited to, execution of
documents and assistance or cooperation (i) in the filing, prosecution, registration, and memorialization of assignment of any applicable
patents, copyrights, mask works or other applications, (ii) in the enforcement of any applicable patents, copyrights, mask works,
Moral Rights, trade secrets or other rights, and (iii) in other legal proceedings related to the Confidential Information or Innovations.

 

(e)            In
the event that the Company is unable for any reason to secure the Executive’s signature to any document required to file, prosecute,
register, or memorialize the assignment of any patent, copyright, mask work or other applications or to enforce any patent, copyright,
mask work, Moral Right, trade secret or other right under any Confidential Information (including improvements thereof) or any Innovations
(including derivative works, improvements, renewals, extensions, continuations, divisionals, continuations in part, continuing patent
applications, reissues, and reexaminations thereof), the Executive hereby irrevocably designates and appoints the Company and the Company’s
duly authorized officers and agents as his agents and attorneys-in-fact to act for and on his behalf and instead of the Executive (i) to
execute, file, prosecute, register and memorialize the assignment of any such application, (ii) to execute and file any documentation
required for such enforcement and (iii) to do all other lawfully permitted acts to further the filing, prosecution, registration,
memorialization of assignment, issuance, and enforcement of patents, copyrights, mask works, Moral Rights, trade secrets or other rights
under the Confidential Information or Innovations, all with the same legal force and effect as if executed by the Executive.

 

(f)            The
term “Innovations” means all processes, improvements, inventions (whether or not protectable under patent laws),
works of authorship, information fixed in any tangible medium of expression (whether or not protectable under copyright laws), moral rights,
mask works, trademarks, trade names, trade dress, trade secrets, know-how, ideas (whether or not protectable under trade secret laws)
and all other subject matter protectable under patent, copyright, moral right, mask work, trademark, trade secret or other laws and includes,
without limitation, all new or useful art, combinations, designs, developments, modifications, derivative works, discoveries, formulae,
techniques and all goodwill associated with any of the foregoing.

 

(g)            The
Executive hereby irrevocably consents to any and all uses and displays, by the Company and its affiliates, agents, representatives and
licensees, of the Executive’s name, voice, likeness, image, appearance, and biographical information in, on or in connection with
any pictures, photographs, audio and video recordings, digital images, websites, television programs and advertising, other advertising
and publicity, sales and marketing brochures, books, magazines, other publications, CDs, DVDs, tapes, and all other printed and electronic
forms and media throughout the world, at any time during but not after the period of his employment by the Company, for all legitimate
commercial and business purposes of the Company (“Permitted Uses”) without further consent from or royalty,
payment, or other compensation to the Executive. the Executive hereby forever waives and releases the Company and its directors, managing
members, officers, employees and agents from any and all claims, actions, damages, losses, costs, expenses, and liability of any kind,
arising under any legal or equitable theory whatsoever at any time during or after the period of his employment by the Company, arising
directly or indirectly from the Company’s and its affiliates’, agents’, representatives’ and licensees’
exercise of their rights in connection with any Permitted Uses.

 

    11

     

    

 

 

9.              Non-Compete;
Non-Solicitation.

 

(a)            The
Executive acknowledges that, in the course of his employment with the Company and/or the Restricted Affiliates (as defined below), he
has become familiar, or will become familiar, with trade secrets and with other confidential information concerning the Company and the
Restricted Affiliates and that his services have been and will be of special, unique and extraordinary value to the Company and the Restricted
Affiliates. the Executive understands that the following restrictions may limit his ability to earn a livelihood in a business similar
to the business of the Company or any of the Restricted Affiliates, but he nevertheless believes that he will receive sufficient consideration
and other benefits as an equity holder and an employee of the Company and as otherwise provided hereunder to clearly justify such restrictions
which, in any event (given his education, skills and ability), the Executive does not believe would prevent him from otherwise earning
a living. The Executive further understands that the provisions of Sections 7 through 9, inclusive, are reasonable and necessary to preserve
the business of the Company and the Restricted Affiliates. “Restricted Affiliate” means any affiliate for which,
during the twenty-four (24) month period preceding the Termination Date, the Executive served as an officer or director or the Executive
provided any material services.

 

(b)            In
light of Section 9(a), the Executive agrees that while the Executive is employed by the Company, he shall not directly or indirectly
own, manage, operate, control, finance or invest in, participate in, consult with, render services for, act as an officer, director, manager,
partner, principal, agent, representative, contractor or advisor of or to, or in any manner engage in or be associated with, hold any
interest in, be employed by or represent any other business competing with the businesses or the services or products of the Company or
the Restricted Affiliates as such businesses and/or services or products exist or are in the process of being formed, developed or acquired
as of the Termination Date. Nothing herein shall prohibit the Executive from being a passive owner of not more than one percent (1%) of
the outstanding stock of any class of a corporation which is publicly traded, so long as the Executive has no active participation in
the business of such corporation.

 

(c)            Furthermore,
in light of Section 9(a), the Executive agrees that:

 

(i)            while
the Executive is employed by the Company and for twelve (12) months thereafter, the Executive shall not directly or indirectly through
another person or entity: (x) induce or attempt to induce any employee or independent contractor of the Company or any Restricted
Affiliate to leave the employ of or engagement with the Company or such Restricted Affiliate, or in any way interfere with the relationship
between the Company or any such Restricted Affiliate, on the one hand, and any employee or independent contractor thereof, on the other
hand; or (y) hire or engage any person who was an employee or independent contractor of the Company until twelve months after such
individual’s relationship with the Company or any Restricted Affiliate has been terminated; provided, that hiring or engaging
an employee or independent contractor who responded to an advertisement of job openings by use of newspapers, magazines, or other media
not directed at individual prospective employees or independent contractors covered by this Section 9(c) shall not violate this
Section 9(c)(i); provided, further, that, notwithstanding the foregoing, this Section 9(c)(i) shall not apply
with respect to those employees or independent contractors who joined the Company or any Restricted Affiliate as a result of a pre-existing
professional relationship with the Executive that was foundational to their current role with the Company or Restricted Affiliate and
who are set forth on Exhibit C of this Agreement (which Exhibit C may be updated from time to time with the consent
of the Company (such consent not to be unreasonably withheld)); and

 

    12

     

    

 

(ii)            while
the Executive is employed by the Company, the Executive shall not directly or indirectly through another person or entity: (x) induce
or attempt to induce any customer (it being understood that the term “customer” as used throughout this Agreement includes
any person or entity that is receiving services from the Company or any Restricted Affiliate or that is directly or indirectly providing
or referring business for the Company or any Restricted Affiliate), supplier, independent contractor, licensee or other business relation
of the Company or any Restricted Affiliate to cease doing business with the Company or any Restricted Affiliate, or in any way interfere
with the relationship between any such customer, supplier, independent contractor, licensee or business relation, on the one hand, and
the Company or any Restricted Affiliate, on the other hand; or (y) solicit any customer of the Company or any Restricted Affiliate
in order to offer products or services similar to those offered by the Company or any Restricted Affiliate.

 

(d)            The
Executive shall inform any prospective or future employer of any and all restrictions contained in Section 9 of this Agreement that
have the potential to impact Executive’s ability to perform the duties of the position for which he is being considered or hired
and may provide such employer with a copy of such restrictions (but no other terms of this Agreement) prior to the commencement of that
employment.

 

(e)            If,
at the time of enforcement of Section 9, a court holds that the restrictions stated herein are unreasonable under the circumstances
then existing, the Executive and the Company agree that the maximum period, scope or geographical area reasonable under such circumstances
shall be substituted for the stated period, scope or area so as to protect the Company to the greatest extent possible under applicable
law from improper competition.

 

(f)            In
the event of any breach or violation by the Executive of any of the restrictions contained in Section 9, any time period specified
herein shall abate during the time of any such breach or violation thereof and that portion remaining at the time of commencement of any
such breach or violation shall not begin to run until such breach or violation has been cured in all respects.

 

10.            Enforcement.
Because the Executive’s services are unique and because the Executive has access to Confidential Information and Company Innovations,
the parties hereto agree that monetary damages alone would be an inadequate remedy for any breach of the provisions of Section 9
of this Agreement. Therefore, in the event of a breach or threatened breach of Section 9 of this Agreement, the Company or its successors
or assigns may, in addition to other rights and remedies existing in their favor at law or in equity, apply to any court of competent
jurisdiction for specific performance and/or injunctive or other relief in order to enforce, or prevent any violations of, the provisions
hereof (without posting a bond or other security) or require the Executive to account for and pay over to the Company all compensation,
profits, moneys, accruals, increments or other benefits derived from or received as a result of any transactions constituting a breach
of the covenants contained in this Agreement, if and when final judgment of a count of competent jurisdiction is so entered against the
Executive. The rights and remedies of the Company under this Agreement are not exclusive of or limited by any other rights or remedies
which they may have, whether at law, in equity, by contract or otherwise, all of which shall be cumulative (and not alternative). Without
limiting the generality of the foregoing, the rights and remedies of the Company under this Agreement, and the obligations and liabilities
of the Executive under this Agreement, are in addition to their respective rights, remedies, obligations and liabilities under the laws
of unfair competition, laws relating to misappropriation of trade secrets and all other laws, rules and regulations. No failure on
the part of any person or entity to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any
person or entity in exercising any power, right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right,
privilege or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude any other or further
exercise thereof or of any other power, right, privilege or remedy. No person or entity shall be deemed to have waived any claim arising
out of this Agreement, or any power, right, privilege or remedy under this Agreement, unless the waiver of such claim, power, right, privilege
or remedy is expressly set forth in a written instrument duly executed and delivered on behalf of such person or entity; and any such
waiver shall not be applicable or have any effect except in the specific instance in which it is given.

 

    13

     

    

 

11.            Representations.
The Executive hereby represents and warrants to the Company that (a) the Executive is entering into this Agreement voluntarily and
that the performance of the Executive’s obligations hereunder will not violate any agreement between the Executive and any other
person, firm, organization or other entity, and (b) the Executive is not bound by the terms of any agreement with any previous employer
or other party to refrain from competing, directly or indirectly, with the business of such previous employer or other party that would
be violated by the Executive’s entering into this Agreement and/or providing services to the Company pursuant to the terms of this
Agreement.

 

12.            Successors.

 

(a)            This
Agreement is personal to the Executive and, without the prior written consent of the Company, shall not be assignable by the Executive
otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the
Executive’s legal representatives.

 

(b)            This
Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns.

 

(c)            The
Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially
all of the business and/or assets of the Company to assume and agree to perform this Agreement in the same manner and to the same extent
that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, “Company”
shall mean the Company as hereinbefore defined and any successor to its business and/or assets as aforesaid which assumes and agrees to
perform this Agreement by operation of law, or otherwise.

 

13.            Miscellaneous.

 

(a)            Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Maryland, without reference to
principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force or effect.

 

(b)            Compensation
Recovery Policy. Executive acknowledges and agrees that, to the extent the Company adopts any claw-back or similar policy pursuant
to the Dodd-Frank Wall Street Reform and Consumer Protection Act or otherwise, and any rules and regulations promulgated thereunder,
he shall take all action necessary or appropriate to comply with such policy (including, without limitation, entering into any further
agreements, amendments or policies necessary or appropriate to implement and/or enforce such policy with respect to past, present and
future compensation, as appropriate).

 

(c)         Whistleblower
Protections and Trade Secrets. Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits Executive
from reporting possible violations of federal law or regulation to any United States governmental agency or entity in accordance with
the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934
or Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation
(including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18
U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive shall not be in breach of this Agreement,
and shall not be held criminally or civilly liable under any federal or state trade secret law (A) for the disclosure of a trade
secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting
or investigating a suspected violation of law, or (B) for the disclosure of a trade secret that is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation
by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and
may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal,
and does not disclose the trade secret, except pursuant to court order.

 

    14

     

    

 

 

(d)            Notices.
All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by overnight
delivery by FedEx or UPS, addressed as follows:

 

If
to the Executive: at the Executive’s most recent address on the records of the Company

 

With a copy to:

 

Kilpatrick Townsend &
Stockton LLP 

1100 Peachtree Street, Suite 2800 

Atlanta, GA 30309 

Attention Mick Cochran and Diane
Prucino

 

If
to the Company:

 

Aziyo Biologics, Inc.

12510 Prosperity Drive 

Suite 1-370 

Silver Spring, MD 20904 

Attention: Board of Directors

 

with a copy to:

 

Latham & Watkins LLP

885 Third Avenue 

New York, NY 10022-4802

Attn: Wesley Holmes and Rifka Singer

 

or to such other address as either party shall
have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by
the addressee.

 

(e)            Sarbanes-Oxley
Act of 2002. Notwithstanding anything herein to the contrary, if the Company determines, in its good faith judgment, that any transfer
or deemed transfer of funds hereunder is likely to be construed as a personal loan prohibited by Section 13(k) of the Securities
Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (the “Exchange Act”),
then such transfer or deemed transfer shall not be made to the extent necessary or appropriate so as not to violate the Exchange Act and
the rules and regulations promulgated thereunder.

 

    15

     

    

 

(f)            Section 409A
of the Code.

 

(i)            To
the extent applicable, this Agreement shall be interpreted in accordance with Section 409A of the Code and Department of Treasury
regulations and other interpretive guidance issued thereunder (together, “Section 409A”). This Agreement
shall be interpreted and administered to maximize the exemptions from Section 409A and, to the extent this Agreement provides for
deferred compensation subject to Section 409A, to comply with Section 409A and to avoid the imposition of tax, interest and/or
penalties upon the Executive under Section 409A. Notwithstanding any provision of this Agreement to the contrary, if the Company
determines that any compensation or benefits payable under this Agreement may be subject to Section 409A, the Company shall work
in good faith with the Executive to adopt such amendments to this Agreement or adopt other policies and procedures (including amendments,
policies and procedures with retroactive effect), or take any other actions, that the Company determines are necessary or appropriate
to avoid the imposition of taxes under Section 409A, including without limitation, actions intended to (i) exempt the compensation
and benefits payable under this Agreement from Section 409A, and/or (ii) comply with the requirements of Section 409A;
provided, however, that this Section 10(d) shall not create an obligation on the part of the Company
to adopt any such amendment, policy or procedure or take any such other action, nor shall the Company have any liability for failing to
do so.

 

(ii)            Any
right to a series of installment payments pursuant to this Agreement is to be treated as a right to a series of separate payments. To
the extent permitted under Section 409A, any separate payment or benefit under this Agreement or otherwise shall not be deemed “nonqualified
deferred compensation” subject to Section 409A to the extent provided in the exceptions in Treasury Regulation Section 1.409A-1(b)(4),
Section 1.409A-1(b)(9) or any other applicable exception or provision of Section 409A. To the extent necessary to comply
with Section 409A, in no event may the Executive, directly or indirectly, designate the taxable year of payment. In particular, any
payments subject to Section 409A that are subject to execution of a waiver and release which may be executed and/or revoked in a
calendar year following the calendar year in which the payment event (such as termination of employment) occurs shall commence payment
only in the calendar year in which the consideration period or, if applicable, release revocation period ends, as necessary to comply
with Section 409A. All payments of nonqualified deferred compensation subject to Section 409A to be made upon a termination
of employment under this Agreement may only be made upon Employee’s “separation from service” from the Company (within
the meaning of Section 409A, a “Separation from Service”).

 

(iii)            To
the extent that any payments or reimbursements provided to the Executive under this Agreement are deemed to constitute compensation to
the Executive to which Treasury Regulation Section 1.409A-3(i)(1)(iv) would apply, subject to any shorter period of time provided
in any Company expense reimbursement policy or in this Agreement, such amounts shall be paid or reimbursed reasonably promptly, but not
later than December 31 of the year following the year in which the expense was incurred. Any such amount eligible for payment or
reimbursement in one year shall not affect the amount eligible for payment or reimbursement in any other taxable year, and the Executive’s
right to such payments or reimbursement of any such expenses shall not be subject to liquidation or exchange for any other benefit.

 

(g)            Severability.
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision
of this Agreement.

 

(h)            Withholding.
The Company may withhold from any amounts payable under this Agreement such federal, state, or local taxes as shall be required to be
withheld pursuant to any applicable law or regulation.

 

 

    16

     

    

 

(i)            No
Waiver. The Executive’s or the Company’s failure to insist upon strict compliance with any provision of this Agreement
or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the Executive
to terminate employment for Good Reason pursuant to Section 3(c) hereof, shall not be deemed to be a waiver of such provision
or right or any other provision or right of this Agreement.

 

(j)            Entire
Agreement. As of the Effective Date, this Agreement constitutes the final, complete and exclusive agreement between the Executive
and the Company with respect to the subject matter hereof and replaces and supersedes any and all other agreements, offers or promises,
whether oral or written, by any member of the Company and its subsidiaries or affiliates, or representative thereof, including without
limitation Prior Agreement.

 

(k)            Amendment.
No amendment or other modification of this Agreement shall be effective unless made in writing and signed by the parties hereto.

 

(l)            Counterparts.
This Agreement and any agreement referenced herein may be executed simultaneously in two or more counterparts, each of which shall be
deemed an original but which together shall constitute one and the same instrument.

 

[SIGNATURES APPEAR ON FOLLOWING PAGE]

 

    17

     

    

 

IN WITNESS WHEREOF, the Executive
has hereunto set the Executive’s hand and, pursuant to the authorization from the Board, the Company has caused these presents to
be executed in its name on its behalf, all as of the day and year first above written.

 

	 	AZIYO BIOLOGICS, INC.
	 	 
	 	By:	/s/ Kevin Rakin
	 	 	Name: Kevin Rakin
	 	 	Title: Chairman of the Board of Directors
	 	 
	 	EXECUTIVE
	 	 
	 	/s/ C. Randal Mills
	 	C. Randal Mills

 

    S-1

     

    

 

EXHIBIT A

 

eXpanded eXistence, LLC

 

     

     

    

 

EXHIBIT B

 

GENERAL RELEASE

 

For valuable consideration,
the receipt and adequacy of which are hereby acknowledged, the undersigned does hereby release and forever discharge the “Releasees”
hereunder, consisting of Aziyo Biologics, Inc., and its partners, subsidiaries, associates, affiliates, successors, heirs, assigns,
agents, directors, officers, employees, representatives, lawyers, insurers, and all persons acting by, through, under or in concert with
them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts,
liens, contracts, agreements, promises, liability, claims, demands, damages, losses, costs, attorneys’ fees or expenses, of any
nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which the undersigned
now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning
of time to the date hereof.  The Claims released herein include, without limiting the generality of the foregoing, any Claims in
any way arising out of, based upon, or related to the employment or termination of employment of the undersigned by the Releasees, or
any of them; any alleged breach of any express or implied contract of employment; any alleged torts or other alleged legal restrictions
on Releasees’ right to terminate the employment of the undersigned; and any alleged violation of any federal, state or local statute
or ordinance including, without limitation, Title VII of the Civil Rights Act of 1964, the Age Discrimination In Employment Act, the
Americans With Disabilities Act, and [__].1 Notwithstanding the foregoing, this general release (the “Release”)
shall not operate to release any rights or claims of the undersigned (i) to payments or benefits under Section 4(a) of
that certain Employment Agreement, effective as of June 21, 2022, between Aziyo Biologics, Inc. and the undersigned (the “Employment
Agreement”), (ii) to payments or benefits under any equity award agreement between the undersigned and the Company,
(iii) with respect to Section 2(b)(iv) of the Employment Agreement, (iv) to accrued or vested benefits the undersigned
may have, if any, as of the date hereof under any applicable plan, policy, practice, program, contract or agreement with the Company,
(v) to any Claims, including claims for indemnification and/or advancement of expenses arising under any indemnification agreement
between the undersigned and the Company or under the bylaws, certificate of incorporation or other similar governing document of the
Company, (vi) to any Claims which cannot be waived by an employee under applicable law or (vii) with respect to the undersigned’s
right to communicate directly with, cooperate with, or provide information to, any federal, state or local government regulator.

 

[IN ACCORDANCE WITH THE OLDER
WORKERS BENEFIT PROTECTION ACT OF 1990, THE UNDERSIGNED IS HEREBY ADVISED AS FOLLOWS:

 

(A)            THE
EXECUTIVE HAS THE RIGHT TO CONSULT WITH AN ATTORNEY BEFORE SIGNING THIS RELEASE;

 

(B)            THE
EXECUTIVE HAS TWENTY-ONE (21) DAYS TO CONSIDER THIS RELEASE BEFORE SIGNING IT; AND

 

(C)            THE
EXECUTIVE HAS SEVEN (7) DAYS AFTER SIGNING THIS RELEASE TO REVOKE THIS RELEASE, AND THIS RELEASE WILL BECOME EFFECTIVE UPON THE EXPIRATION
OF THAT REVOCATION PERIOD.]

 

The undersigned represents and
warrants that there has been no assignment or other transfer of any interest in any Claim which the Executive may have against Releasees,
or any of them, and the undersigned agrees to indemnify and hold Releasees, and each of them, harmless from any liability, Claims, demands,
damages, costs, expenses and attorneys’ fees incurred by Releasees, or any of them, as the result of any such assignment or transfer
or any rights or Claims under any such assignment or transfer.  It is the intention of the parties that this indemnity does not require
payment as a condition precedent to recovery by the Releasees against the undersigned under this indemnity.

 

 

1 Applicable state law references to be included.

 

     

     

    

 

Notwithstanding anything herein, the undersigned acknowledges and
agrees that, pursuant to 18 USC Section 1833(b), the undersigned will not be held criminally or civilly liable under any federal
or state trade secret law for the disclosure of a trade secret that is made: (i) in confidence to a federal, state, or local government
official, either directly or indirectly, or to an attorney, and solely for the purpose of reporting or investigating a suspected violation
of law; or (ii) in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.

 

The undersigned agrees that
if the Executive hereafter commences any suit arising out of, based upon, or relating to any of the Claims released hereunder or in any
manner asserts against Releasees, or any of them, any of the Claims released hereunder, then the undersigned agrees to pay to Releasees,
and each of them, in addition to any other damages caused to Releasees thereby, all attorneys’ fees incurred by Releasees in defending
or otherwise responding to said suit or Claim.

 

The undersigned further understands
and agrees that neither the payment of any sum of money nor the execution of this Release shall constitute or be construed as an admission
of any liability whatsoever by the Releasees, or any of them, who have consistently taken the position that they have no liability whatsoever
to the undersigned.

 

IN WITNESS WHEREOF, the undersigned
has executed this Release this ____ day of ___________, ____.

 

 

 

 

    A-2

     

    

 

EXHIBIT C

 

    A-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00345-of-00352.parquet"}]]